{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:37:06Z","timestamp":1790113026728,"version":"4.0.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81373334"],"award-info":[{"award-number":["81373334"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ijpharm.2017.03.034","type":"journal-article","created":{"date-parts":[[2017,3,20]],"date-time":"2017-03-20T18:30:48Z","timestamp":1490034648000},"page":"203-216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"title":["Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity"],"prefix":"10.1016","volume":"523","author":[{"given":"Songlei","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghua","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhi","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2017.03.034_bib0005","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1734-1140(09)70018-0","article-title":"Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron","volume":"61","author":"\u0160im\u016fnek","year":"2009","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0010","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2249.2011.04515.x","article-title":"Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment","volume":"167","author":"Allavena","year":"2012","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0020","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1021\/cr000407m","article-title":"Chemical diversity in the sialic acids and related \u03b1-keto acids: an evolutionary perspective","volume":"102","author":"Angata","year":"2002","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0025","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: back to Virchow?","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0030","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1158\/1078-0432.CCR-07-1562","article-title":"Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy","volume":"14","author":"Blansfield","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0035","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.addr.2008.08.005","article-title":"Active targeting schemes for nanoparticle systems in cancer therapeutics","volume":"60","author":"Byrne","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0040","series-title":"Guide for the Care and Use of Laboratory Animals","author":"Care I.o.L.A.R.C.o","year":"1985"},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0045","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1158\/1078-0432.CCR-07-1441","article-title":"Therapeutic nanoparticles for drug delivery in cancer","volume":"14","author":"Cho","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0050","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0055","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jconrel.2006.12.002","article-title":"Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy","volume":"118","author":"Cui","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0060","article-title":"Dioscorea bulbifera polysaccharide and cyclophosphamide combination enhances anti-cervical cancer effect and attenuates immunosuppression and oxidative stress in mice","volume":"5","author":"Cui","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0065","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2010.08.027","article-title":"To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery","volume":"148","author":"Danhier","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0070","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ijpharm.2015.12.066","article-title":"Improved antitumor activity of epirubicin-loaded CXCR4-targeted polymeric nanoparticles in liver cancers","volume":"500","author":"Di-Wen","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0075","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1016\/S1470-2045(14)70263-3","article-title":"Cancer-related inflammation and treatment effectiveness","volume":"15","author":"Diakos","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0080","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1189\/jlb.0905495","article-title":"Monocyte\/macrophage infiltration in tumors: modulators of angiogenesis","volume":"80","author":"Dirkx","year":"2006","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0085","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0031-6997(24)01426-1","article-title":"Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors","volume":"51","author":"Drummond","year":"1999","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0090","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.2165\/11207510-000000000-00000","article-title":"Pegylated liposomal doxorubicin","volume":"71","author":"Duggan","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0095","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1021\/acs.biomac.5b00550","article-title":"Cholesterol modified self-Assemblies and their application to nanomedicine","volume":"16","author":"Ercole","year":"2015","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0100","first-page":"16","article-title":"Liposomes as vehicles for targeted therapy of cancer. Part 2: clinical development","volume":"12","author":"Harrington","year":"2000","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0105","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.addr.2016.03.004","article-title":"Editorial: targeting tumor microenvironment heterogeneity","volume":"99","author":"Hida","year":"2016","journal-title":"Adv. Drug Deliv. Rev. 99 Part B"},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0110","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1021\/acs.biomac.6b00956","article-title":"Tumor microenvironment-Responsive nanoparticle delivery of chemotherapy for enhanced selective cellular uptake and transportation within tumor","volume":"17","author":"Huang","year":"2016","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0115","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.biomaterials.2016.03.009","article-title":"Targeted delivery of let-7b to reprogramme tumor-associated macrophages and tumor infiltrating dendritic cells for tumor rejection","volume":"90","author":"Huang","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0120","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1093\/jnci\/90.21.1648","article-title":"Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents","volume":"90","author":"Joseph","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0125","first-page":"6","article-title":"Leishmania donovani cell surface sialoglycans regulate susceptibility for siglec mediated macrophage invasion and parasite survival","volume":"1","author":"Karmakar","year":"2012","journal-title":"J. Mol. Biochem."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0130","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijpharm.2016.05.047","article-title":"Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors","volume":"509","author":"Kibria","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0135","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/path.4824","article-title":"CAFs and TAMs: maestros of the tumour microenvironment","volume":"241","author":"Komohara","year":"2017","journal-title":"The Journal of Pathology"},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0140","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.immuni.2016.01.014","article-title":"CD45 phosphatase inhibits STAT3 transcription factor activity in myeloid cells and promotes tumor-Associated macrophage differentiation","volume":"44","author":"Kumar","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0145","doi-asserted-by":"crossref","first-page":"E211","DOI":"10.1016\/j.jss.2009.05.026","article-title":"Significance of M2-Polarized tumor-associated macrophage in pancreatic cancer","volume":"167","author":"Kurahara","year":"2011","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0150","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jconrel.2012.07.010","article-title":"Analysis on the current status of targeted drug delivery to tumors","volume":"164","author":"Kwon","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0155","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.biomaterials.2015.10.046","article-title":"Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles","volume":"76","author":"Li","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0160","doi-asserted-by":"crossref","first-page":"7785","DOI":"10.1016\/j.biomaterials.2012.07.022","article-title":"PET imaging of tumor associated macrophages using mannose coated 64Cu liposomes","volume":"33","author":"Locke","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0165","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-10-112","article-title":"The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time","volume":"10","author":"Ma","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0170","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ejps.2011.11.014","article-title":"Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats","volume":"45","author":"Ma","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0175","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nri3737","article-title":"Siglec-mediated regulation of immune cell function in disease","volume":"14","author":"Macauley","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0180","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10555-006-9001-7","article-title":"Role of tumor-associated macrophages in tumor progression and invasion","volume":"25","author":"Mantovani","year":"2006","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0185","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.progpolymsci.2006.03.001","article-title":"Michael addition reactions in macromolecular design for emerging technologies","volume":"31","author":"Mather","year":"2006","journal-title":"Prog. Polym. Sci."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0190","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/joim.12470","article-title":"The immune system and cancer evasion strategies: therapeutic concepts","volume":"279","author":"Muenst","year":"2016","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0195","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ejpb.2014.04.016","article-title":"Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice","volume":"88","author":"Nasr","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0200","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1046\/j.1365-2567.1999.00827.x","article-title":"Macrophage-tumour cell interactions: identification of MUC1 on breast cancer cells as a potential counter-receptor for the macrophage-restricted receptor, sialoadhesin","volume":"98","author":"Nath","year":"1999","journal-title":"Immunology"},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0205","doi-asserted-by":"crossref","first-page":"14642","DOI":"10.1039\/c3ra40883c","article-title":"Radio-opaque theranostic nanoemulsions with synergistic anti-cancer activity of paclitaxel and Bcl-2 siRNA","volume":"3","author":"Oh","year":"2013","journal-title":"RSC Adv."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0210","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jconrel.2015.12.037","article-title":"A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma: anti-angiogenic and anti-tumor effects","volume":"223","author":"Piaggio","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0215","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijpharm.2011.07.021","article-title":"Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery","volume":"419","author":"Qin","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0220","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijpharm.2015.12.053","article-title":"Formulation and in vitro efficacy of liposomes containing the Hsp90 inhibitor 6BrCaQ in prostate cancer cells","volume":"499","author":"Sauvage","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0225","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijpharm.2014.10.014","article-title":"Liposomes for targeting hepatocellular carcinoma: use of conjugated arabinogalactan as targeting ligand","volume":"477","author":"Shah","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0230","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1016\/j.biomaterials.2014.03.022","article-title":"The anticancer efficacy of pixantrone-loaded liposomes decorated with sialic acid\u2013octadecylamine conjugate","volume":"35","author":"She","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0235","first-page":"5857","article-title":"Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression","volume":"60","author":"Shimura","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0240","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.ejca.2006.01.003","article-title":"Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy","volume":"42","author":"Sica","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0245","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1189\/jlb.0609385","article-title":"Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation","volume":"86","author":"Solinas","year":"2009","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0250","first-page":"2307","article-title":"Self-assembled micelles of novel amphiphilic copolymer cholesterol-coupled F68 containing cabazitaxel as a drug delivery system","volume":"9","author":"Song","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0255","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.biomaterials.2016.09.001","article-title":"Development of a multi-target peptide for potentiating chemotherapy by modulating tumor microenvironment","volume":"108","author":"Song","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0260","first-page":"316","article-title":"Pharmacodynamics of liposomes modified with different chain length of sialic acid derivatives","volume":"51","author":"Song","year":"2016","journal-title":"Acta Pharm. Sin."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0265","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ejps.2016.08.029","article-title":"Evaluation of the antitumor effect of dexamethasone palmitate and doxorubicin co-loaded liposomes modified with a sialic acid\u2013octadecylamine conjugate","volume":"93","author":"Sun","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0270","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.colsurfb.2015.02.043","article-title":"Biodegradable polymeric nanoparticles for oral delivery of epirubicin: in vitro, ex vivo, and in vivo investigations","volume":"128","author":"Tariq","year":"2015","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0275","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jconrel.2012.07.013","article-title":"Anticancer nanomedicine and tumor vascular permeability; where is the missing link","volume":"164","author":"Taurin","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0280","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejps.2010.06.008","article-title":"Enhanced efficacy of functionalized epirubicin liposomes in treating brain glioma-bearing rats","volume":"41","author":"Tian","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0285","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jnci\/djm135","article-title":"Drug resistance and the solid tumor microenvironment","volume":"99","author":"Tr\u00e9dan","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0290","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ijpharm.2007.02.011","article-title":"Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation","volume":"338","author":"Yang","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0295","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ejpb.2014.10.006","article-title":"Coencapsulation of epirubicin and metformin in PEGylated liposomes inhibits the recurrence of murine sarcoma S180 existing CD133+ cancer stem-like cells","volume":"88","author":"Yang","year":"2014","journal-title":"Eur. Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0300","doi-asserted-by":"crossref","DOI":"10.1111\/j.1349-7006.2012.02411.x","article-title":"Impact of tumor-associated macrophages on invasive ductal carcinoma of the pancreas head","volume":"103","author":"Yoshikawa","year":"2012","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0305","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.phymed.2006.03.010","article-title":"Effects of Hydrocotyle sibthorpioides extract on transplanted tumors and immune function in mice","volume":"14","author":"Yu","year":"2007","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0310","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijpharm.2016.10.051","article-title":"Polysialic acid-modifying liposomes for efficient delivery of epirubicin, in-vitro characterization and in-vivo evaluation","volume":"515","author":"Zhang","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0315","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.biomaterials.2015.07.053","article-title":"Nanoparticle delivery of CDDO-Me remodels the tumor microenvironment and enhances vaccine therapy for melanoma","volume":"68","author":"Zhao","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpharm.2017.03.034_bib0320","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.colsurfb.2010.11.023","article-title":"Sialic acid surface decoration enhances cellular uptake and apoptosis-inducing activity of selenium nanoparticles","volume":"83","author":"Zheng","year":"2011","journal-title":"Colloids Surf. B Biointerfaces"}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517317302107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517317302107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T14:21:30Z","timestamp":1750170090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517317302107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0378517317302107"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2017.03.034","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2017.03.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}